Cancer of the Corpus Uteri in Black Women

  • John G. Boyce
  • Rachel G. Fruchter


The differences between racial/ethnic groups in cancer incidence and survival are greater for cancer of the uterine corpus than for any other major cancer site. According to 1978–1981 data from the Surveillance, Epidemiology, and End Results (SEER) Program (Baquet et al. 1986), the incidence of corpus cancer ranged from 2.6 per 100,000 Native Americans to 27.1 per 100,000 Native Hawaiians with a White:Black ratio of 1.9 (Table 1). The five-year survival ranged from a high of 88% in Whites to 57% in Blacks, a difference of 31%. For breast cancer, in comparison, the White:Black incidence ratio was only 1.2 and the difference in five-year survival was only 12%. Since corpus cancer is the fourth most frequent cancer in U.S. women, with 35,000 new cases estimated for 1987, its diagnosis and treatment involves much expensive medical care, and its prevention is clearly of great significance. The existence of differences between populations often suggests that some aspects of a disease are indeed preventable and thus justifies a detailed analysis of ethnic differences in all factors that contribute to the incidence and mortality of corpus cancer.


Endometrial Cancer White Woman Black Woman Endometrial Carcinoma Uterine Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Cancer Society: Cancer Facts and Figures —1987, p 17. New York: American Cancer Society, 1987.Google Scholar
  2. Antunes CMF, Stolley PD, Rosenshein NB, et al: Endometrial cancer and estrogen use: Report of a large case-control study. N Engl J Med 1979; 300:9–13.PubMedCrossRefGoogle Scholar
  3. Austin DF, Roe KM: Increase in cancer of the corpus uteri in the San Francisco-Oakland Standard Metropolitan Statistical Area, 1965–75. JNCI 1979; 62:13–16.PubMedGoogle Scholar
  4. Baquet CR, Ringen K, Pollack ES, et al: Cancer Among Blacks and Other Minorities: Statistical Profiles. National Cancer Institute. Bethesda, MD: NIH Publication No 86–2785, 1986.Google Scholar
  5. Centers for Disease Control Cancer and Steroid Ho0072mone Study: Oral contraceptive use and the risk of endometrial cancer. JAMA 1983; 249:1600–1604.CrossRefGoogle Scholar
  6. Collins J, Donner A, Allen LH, Adams O: Oestrogen use and survival in endometrial cancer. Lancet 1980; 2:961–964.PubMedCrossRefGoogle Scholar
  7. De Waard F. Uterine corpus. In Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention, 2nd ed, Philadelphia: Saunders, 1982, pp 901–908.Google Scholar
  8. Easterday CL, Grimes DA, Riggs JA: Hysterectomy in the United States. Obstet Gynecol 1983; 62:203–212.PubMedGoogle Scholar
  9. Elwood JM, Boyes DA: Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol 1980; 10:173–187.PubMedCrossRefGoogle Scholar
  10. Elwood JM, Cole P, Rothman K, Kaplan SD: Epidemiology of endometrial cancer. JNCI 1977;59:1055–1060.PubMedGoogle Scholar
  11. Fruchter RG, Boyce JG: Delays in diagnosis and stage of disease in gynecologic cancer.Cancer Detect Prev 1981; 4:481–486.PubMedGoogle Scholar
  12. Gambrell RD, Bagnell CA, Greenblatt RB: Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review. Am J Obstet Gynecol 1983; 146:696–707.PubMedGoogle Scholar
  13. Gray LA, Christopherson WM, Hoover RN: Estrogens and endometrial carcinoma. Obstet Gynecol 1977; 49:385–389.PubMedGoogle Scholar
  14. Haenszel W, Hillhouse M: Uterine-cancer morbidity in New York City and its relation to the pattern of regional variation within the United States. JNCI 1959; 22:1157–1181.PubMedGoogle Scholar
  15. Harlow BL, Weiss NS, Lofton S: The epidemiology of sarcomas of the uterus. JNCI 1986; 76:399–402.PubMedGoogle Scholar
  16. Horm JW, Asire AJ, Young AJ, et al: Cancer Incidence and Mortality in the United States, SEER, 1973–81. US Department of Health and Human Services. Bethesda, MD: NIH Publication No 85–1837, 1985.Google Scholar
  17. Howe HL: Age-specific hysterectomy and oophorectomy prevalence rates and the risks for cancer of the reproductive system. Am J Public Health 1984; 74:560–563.PubMedCrossRefGoogle Scholar
  18. Hulka BS, Fowler WC, Kaufman DG, et al: Estrogen and endometrial cancer: Cases and two control groups from North Carolina. Am J Obstet Gynecol 1980; 137:92–101.PubMedGoogle Scholar
  19. Kelsey J: Epidemiology of osteoporosis. In Gold EB (ed): The Changing Risk of Disease in Women. Lexington, MA: Collamore Press, 1984, pp 287–298.Google Scholar
  20. Kennedy D, Baum C, Forbes MB: Noncontraceptive estrogens and progestins: Use patterns over time. Obstet Gynecol 1985; 65:441–446.PubMedGoogle Scholar
  21. Koss LG, Schreiber K, Oberlander SG, et al: Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984; 64:1–11.PubMedGoogle Scholar
  22. Mack TM, Pike MC, Henderson BE, et al: Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976; 294:1262–1267.PubMedCrossRefGoogle Scholar
  23. McDonald TW, Annegers JF, O’Fallon WM, et al: Exogenous estrogen and endometrial carcinoma: Case-control and incidence study. Am J Obstet Gynecol 1977; 127:572–580.PubMedGoogle Scholar
  24. McTiernan A, Chu J, Thomas DB: Cancer incidence in Caucasians living in the Pacific Basin. NCI Monogr 1985; 69:65–72.Google Scholar
  25. National Center for Health Statistics: Height and Weight of Adults Ages 18–74 Years by Socioeconomic and Geographic Variables: United States 1971–74. US Vital and Health Statistics Series 11, No 224. Washington DC: US Government Printing Office, 1985.Google Scholar
  26. Petterson F. Annual Report on the Results of Treatment in Gynecological Cancer, Vol 19. Stockholm, Sweden: Radiumhemmet, 1985, pp 123–136.Google Scholar
  27. Polednak AP: Incidence of soft-tissue cancers in Blacks and Whites in New York State. Int J Cancer 1986; 38:21–26.PubMedCrossRefGoogle Scholar
  28. Russell-Briefel R, Ezzati T, Perlman J: Prevalence and trends in oral contraceptive use in premenopausal females aged 12–54 years, United States, 1971–80. Am J Public Health 1985;75:1173–1176.PubMedCrossRefGoogle Scholar
  29. Silverberg SG, Makowski EL, Roche WD: Endometrial carcinoma in women under 40 years of age. Cancer 1977; 39:592–598.PubMedCrossRefGoogle Scholar
  30. Smith DC, Prentice R, Thompson DJ, et al: Association of exogenous estrogen and endometrial cancer. N Engl J Med 1975; 293:1164–1167.PubMedCrossRefGoogle Scholar
  31. Steinhorn SC, Meyers MH, Hankey BF, Pelham VF: Factors associated with survival differences between Black and White women with cancer of the uterine corpus. Am J Epidemiol 1986; 124:85–93.PubMedGoogle Scholar
  32. Waterhouse J, Muir C, Shanmugaratnam K, et al: Cancer Incidence in Five Continents. IARC Scientific Publications No 42. Lyon, France: International Agency for Researchagainst Cancer, 1982.Google Scholar
  33. Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293:1167–1170.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • John G. Boyce
  • Rachel G. Fruchter

There are no affiliations available

Personalised recommendations